Microbot Medical initiated with a Buy at B. Riley

B. Riley initiated coverage of Microbot Medical (MBOT) with a Buy rating and $5 price target Microbot markets the Liberty Endovascular Robotic System, the first and only single-use, remotely operated robotic platform cleared by the FDA for peripheral vascular procedures, the analyst tells investors in a research note. The firm expects the company to gain commercial traction faster than its robotic peers given its position as the only FDA-cleared system, “clinically validated” benefits including eliminating radiation exposure to operators, and a disposable model that bypasses capital equipment procurement entirely.